Press Release: Novartis announces new -2-

reappraisal. Blood. 2012:120(18):3647-3656

[4] Piel F, Steinberg M, Rees D. Sickle cell disease. N Engl J Med.

2017;376(16):1561-1573.

[5] Ballas SK, Lusardi M. Hospital readmission for acute adult sickle

cell painful episodes: frequency, etiology, and prognostic significance.

Am J Hematol. 2005;79(1):17-25.

[6] Ataga KI, Kutlar A, Kanter J et al. Crizanlizumab for the

Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb

2;376(5):429-439.

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Eric Althoff Michael Billings

Novartis Global Media Relations Benign Hematology Communications

+41 61 324 7999 (direct) +1 862 778 8656 (direct)

+41 79 593 4202 (mobile) +1 201 400 1854 (mobile)

eric.althoff@novartis.com michael.billings@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF): http://hugin.info/134323/R/2227491/874513.pdf

This announcement is distributed by West Corporation on behalf of West

Corporation clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

December 01, 2018 10:15 ET (15:15 GMT)